Palvella Therapeutics
PVLA
88 hedge funds and large institutions have $68.8M invested in Palvella Therapeutics in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 33 reducing their positions, and 16 closing their positions.
34% more call options, than puts
Call options by funds: $67K | Put options by funds: $50K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.03% less ownership
Funds ownership: 0.82% → 0.79% (-0.03%)
8% less funds holding
Funds holding: 96 → 88 (-8)
30% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 33
36% less capital invested
Capital invested by funds: $107M → $68.8M (-$38.4M)
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$6.77M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.42M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$728K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$707K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$485K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$5.41M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$5.2M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.42M |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$930K |
| 5 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$837K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAM
101
Meeder Asset Management
Dublin,
Ohio
| – | -$9K | -36 | Closed |
|
102
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$6.38K | -28 | Closed |
|
|
TC
103
Truvestments Capital
Sarasota,
Florida
| – | -$2K | -9 | Closed |
|
PVLA Hedge Fund Activity: Q3 2020 in Review
88 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2020, worth a combined $68.8M — down 36% from $107M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PVLA and 8 opened new positions — a net loss of 8 holders — while 33 trimmed existing stakes and 23 added.
The largest buyer was BVF Inc, adding an estimated $6.77M. The largest seller was Aquilo Capital Management, cutting an estimated $5.41M.
- 88 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2020, down from 96 in Q2 2020.
- Funds reported $68.8M of Palvella Therapeutics stock for Q3 2020, down 36% quarter-over-quarter.
- 8 funds opened new Palvella Therapeutics positions in Q3 2020 and 16 closed out, a net change of -8 holders.
- The largest Palvella Therapeutics buyer in Q3 2020 was BVF Inc, an estimated $6.77M added.
- The largest Palvella Therapeutics seller in Q3 2020 was Aquilo Capital Management, an estimated $5.41M sold.
Based on aggregated 13F filings for Q3 2020.